Introduction {#Sec1}
============

Celiac disease (celiac sprue, CD) is a polygenic chronic enteropathy, resulting from an aberrant cellular response to gluten peptides, which are storage proteins in wheat, barley, and rye. CD is one of the most common disorders affecting humans with prevalence in populations of Caucasian descent close to 1:100 with the majority of patients awaiting diagnosis \[[@CR1]\]. The only treatment is a lifelong strict gluten-free diet.

Increased risks of venous thrombosis, cardiovascular disease, and stroke have been demonstrated in adults with longstanding untreated CD \[[@CR2]--[@CR6]\]. Moreover, a frequent finding in CD is hyperhomocysteinemia, which may be related to the development of vascular disease in CD patients \[[@CR2], [@CR7]\]. Compromised absorptive capacities of vitamins B~6~, B~12~, and folate in untreated patients make them susceptible to homocysteine abnormalities \[[@CR1], [@CR8]\].

Folate is a carrier of one-carbon fragments, which it transfers to various biochemical targets. 5,10-Methylenetetrahydrofolate reductase (MTHFR, EC 1.5.1.20) is one of the critical folate-metabolizing enzymes \[[@CR9]\]. It was shown that subjects homozygous for the c677C\>T (rs1801133) polymorphism of the *MTHFR* gene (MIM 607093) had significantly elevated total homocysteine concentrations, whereas the total homocysteine concentration in the CC subjects did not vary significantly from that in the CT subjects \[[@CR10]\]. Genome-wide association study (GWAS) of determinants of plasma homocysteine level showed that the *MTHFR* c.677C\>T is the most significant gene variant \[[@CR11]\]. Reduced MTHFR activity could alter the distribution of folate derivatives and the TT genotype is usually associated with a 10--30% reduction in circulating folate \[[@CR12]\]. Either 5-methyltetrahydrofolate, betaine or S-methylmethionine can supply methyl groups for remethylation of homocysteine to methionine. These reactions are catalyzed by vitamin B~12~-dependent 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR, EC 2.1.1.13), betaine-homocysteine methytransferase 1 and 2 (BHMT1, EC 2.1.1.5; BHMT2, EC 2.1.1.5), respectively. Cystathionine β-synthase (CBS, EC 4.2.1.22) is involved in the vitamin B~6~-dependent transsulfuration pathway, which converts homocysteine to cystathionine, a substrate for cysteine synthesis \[[@CR9]\]. The methylenetetrahydrofolate dehydrogenase gene (*MTHFD1,* MIM 172460) encodes a trifunctional enzyme, which catalyses the sequential interconversion of tetrahydrofolate. Methionine synthase reductase (MTRR, EC 2.1.1.135) is involved in the regeneration of methylcobalamin, a cofactor for MTR. The polymorphic variant rs1801198 of the gene for the transcobalamin II protein (*TCN2*, MIM 613441) has been reported to potentially interfere with the intracellular availability of vitamin B~12~ \[[@CR13]\].

In the prospective study of 40 newly-diagnosed celiac patients and 126 control subjects, Saibeni et al. \[[@CR8]\] observed that folate and vitamin B~12~ levels were independently and inversely associated with homocysteine levels, and homozygosity for the *MTHFR* c.677C\>T polymorphism tended to reach statistical significance as a risk factor. Abnormalities of homocysteine levels in CD do not consistently improve with a gluten-free diet \[[@CR14], [@CR15]\]. It is noteworthy that the small study by Wilcox and Mattia \[[@CR14]\] revealed a possible excessive expression of the *MTHFR* c.677C\>T gene variant in CD patients. Moreover, it is intriguing that despite the high frequency of folate deficiency in untreated celiac patients \[[@CR16]\], the suspected association between maternal CD and an increased risk of nonsyndromic structural malformations in CD patient offspring has received no support from large studies focused on unfavourable outcomes of pregnancy in untreated CD women \[[@CR17], [@CR18]\]. The suspected association was considered to be a consequence of hyperhomocysteinemia due to folate deficiency \[[@CR19]--[@CR21]\].

Recently, despite negative clinical observations in untreated CD women, Arakeri et al. \[[@CR22]\] postulated a relationship between cleft lip and palate and parental CD, which may be a result of disturbed methylation. Interestingly, there are studies revealing that genetic factors are related to unfavourable pregnancy outcomes in maternal CD, but not the degree of clinical severity of CD \[[@CR23]\]. Nuclear magnetic resonance (NMR)-based metabonomics have demonstrated a characteristic signature related to methyl group metabolism for CD \[[@CR24]\]. Polymorphic variants of genes involved in methyl group metabolism may modify the susceptibility of carriers to hyperhomocysteinemia and to having children with potentially folate/cobalamin-responsive congenital malformations \[[@CR9]\].

Therefore, we hypothesized the existence of differences between CD patients and the general population in the distribution of polymorphic variants of genes involved in homocysteine metabolism. Using case--control study-based data, we investigated 10 polymorphic variants in 8 genes involved in methyl group homeostasis, which were previously tested by our group as maternal genetic risk factors for orofacial clefts in the Polish population \[[@CR25], [@CR26]\].

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

Peripheral blood samples from 134 patients with celiac disease (age range 2--30 years, the male-to-female ratio was 0.52) were obtained from two Polish referral centers for CD (Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz and Institute of Mother and Child, Warsaw). All affected individuals were diagnosed according to the revised ESPGHAN criteria showing a Marsh III lesion (duodenal villous atrophy with intraepithelial lymphocytosis) and positive tests for anti-endomysium antibodies \[[@CR1]\]. In addition, 160 healthy blood donors were used as controls. Frozen whole blood samples for DNA isolation were only available and therefore the participants were not tested for homocysteine and vitamin B levels. All participants were Caucasian of Polish origin. Written informed consent was obtained from all individuals before enrolment in the study. The study was approved by the local Ethics Committee.

Single nucleotide polymorphism selection and genotyping {#Sec4}
-------------------------------------------------------

10 selected single nucleotide polymorphisms (SNPs), with the exception of *TCN2* rs1801198, had been previously tested by us as maternal risk factors for orofacial clefts in the Polish population \[[@CR25], [@CR26]\], and are listed in Table [1](#Tab1){ref-type="table"}. This set of SNPs was chosen based on the following criteria: HapMap validation status, functional relevance and importance, and a minor allele frequency (MAF) of \>0.05 in the Caucasian population.Table 1Characteristics of the polymorphisms genotyped in the data setGene symbolGene namers no.SNP function^a^Protein effectLocation^b^Alleles^c^MAF^d^*BHMT1*Betaine-homocysteine methyltransferasers7356530Intergenic--chr5:78400908A/g0.44rs3733890MissenseGln239Argchr5:78421959a/G0.28*BHMT2*Betaine-homocysteine methyltransferase 2rs526264Intron--chr5:78378410a/T0.43rs625879Intron--chr5:78381689G/t0.43*CBS*Cystathionine-beta-synthase844ins68--^e^--chr21:44483195W/ins^f^0.06*MTHFD1*Methylenetetrahydrofolate dehydrogenase 1rs2236225MissenseArg653Glnchr14:64908845C/t0.44*MTHFR*5,10-Methylenetetrahydrofolate reductasers1801133MissenseAla222Valchr1:11856378C/t0.32*MTR*5-Methyltetrahydrofolate-homocysteine methyltransferasers1805087MissenseAsp919Glychr1:237048500A/g0.25*MTRR*Methionine synthase reductasers1801394MissenseMet22Ilechr5:7870973A/g0.45*TCN2*Transcobalamin IIrs1801198MissenseArg259Prochr22:31011610C/g0.44^a^According to the Single Nucleotide Polymorphism database (dbSNP)^b^Based on UCSC Human Genome Browser, February 2009 human reference sequence (GRCh37)^c^Uppercase denotes the more frequent allele in the control samples^d^MAF, minor allele frequency calculated from the control samples^e^844ins68 is a 68 bp insertion in exon 8 of *CBS*^f^W, wild allele; ins, allele with insertion

DNA was isolated from peripheral blood lymphocytes by salt extraction. Genotyping of all but three polymorphisms was carried out by polymerase chain reaction (PCR), followed by digestion with the appropriate restriction enzyme (PCR-RFLP) and agarose-gel electrophoresis (performed according to the manufacturer's instructions, Fermentas, Vilnius, Lithuania). *BHMT1* (MIM602888) rs3733890, *BHMT2* (MIM 605932) rs625879, and *MTRR* (MIM602568) rs1801394 were genotyped by high-resolution melting curve analysis (HRM) on the LightCycler 480 system (Roche Diagnostics, Mannheim, Germany; <http://www.gene-quantification.de/hrm.html>). The HRM analysis results were confirmed by DNA sequencing using ABI Prism BigDye Terminator Cycle Sequencing kit and an ABI Prism 3739 capillary sequencer (Applied Biosystems, Foster City, CA, USA). Samples that failed the genotyping assays were excluded from statistical analyses. Details of SNPs selected for genotyping, and the methods of their analysis, are presented in Table [2](#Tab2){ref-type="table"}.Table 2Conditions for the identification of methyl group metabolism gene polymorphismsGene symbolrs no.Primers for PCR amplification (5′--3′)Annealing temperature (°C)PCR product length (bp)Restriction enzymeAlleles^a^Restriction fragment length (bp)Genotype \[1\]\[1\]^b^Genotype \[2\]\[2\]^b^*BHMT1*rs7356530F: GCTTACCACAAGTGAAATGACG\
R: GGAACTACGCAAATAGCCATC64.5549*Nla*IIIA/g316, 233316, 121, 112rs3733890F: GTTTCTGGTGCATCCCTAAGT\
R: TTGCAGTCAGGAGTGTGGTA64190--^c^a/G--^c^--^c^*BHMT2*rs526264F: TGGCAAAGACAGGGAGTAGC\
R: CAGCTTCTTCAACGTGCTCA66576*Mbo*Ia/T576329, 247rs625879 F: TTCTCCCTTTGTCCAGCAAC\
R: TTGAATCTGAGGAGGCCAGA66136--^c^G/t--^c^--^c^*CBS*844ins68F: GGGTTTCTCATCCTGCCTCT\
R: TCGTCCCCCAGTCTACTTTG64.2470--W/ins^d^470538*MTHFD1*rs2236225F: TTCTTCTCATTCTTCCTCACACC\
R: TCTGCTCCAAATCCTGCTTC66416*Msp*IC/t255, 161416*MTHFR*rs1801133F: AGGCTGTGCTGTGCTGTTG\
R: CGCTGTGCAAGTTCTGGAC67477*Hin*fIC/t425, 52260, 165, 52*MTR*rs1805087F: GTTGGTGAAGGGAGAAGAAATG\
R: CTGAAGAATGGGGGTCTGTG60583*Hae*IIIA/g583381, 202*MTRR*rs1801394F: CCCCATTTTTCAGTTTCACTGT\
R: CACTTCCCAACCAAAATTCTTC53228--^c^A/g--^c^--^c^*TCN2*rs1801198F: GCATTACAGGTGGGAAAGAGAC\
R: CCAGGGATCTCCATTTACTGTC67.2525*Mva*IC/g363, 118, 24, 17, 3481, 24, 17, 3^a^Uppercase denotes the more frequent allele in the control samples^b^\[1\], allele 1; \[2\], allele 2^c^Genotyping with the use of high resolution melting curve analysis (HRM)^d^W, wild allele; ins, allele with insertion

Statistical analysis {#Sec5}
--------------------

For each marker, MAF, and Chi-square test for Hardy--Weinberg equilibrium (HWE) were computed in CD patients and in controls. The differences in allele and genotype frequencies between cases and controls were determined using standard Chi-square and Fisher exact tests. Statistical power was evaluated by Power and Sample Size Calculation program (<http://medipe.psu.ac.th/episoft/pssamplesize/>), Supplementary Table 1. Associations between the investigated polymorphisms and incidence of CD were tested using the nonparametric and genetic model-free Multifactor Dimensionality Reduction (MDR) approach (MDR version 2.0 beta 5). Statistical significance was evaluated using a 1,000-fold permutation test (MDR permutation testing module 0.4.9 alpha). The MDR software and the MDR permutation testing module are freely available from <http://www.epistasis.org>. A *P*-value of \<0.05 was considered statistically significant.

Results {#Sec6}
=======

None of the tested SNPs demonstrated deviation from Hardy-Weinberg equilibrium in either CD patients or controls. In the patient cases, the MAF for all markers was at least 4%. The genotype frequencies are summarised in Table [3](#Tab3){ref-type="table"}. For the analyzed polymorphisms of *MTHFR*, *MTRR*, *MTHFD1*, *CBS (MIM 613381)*, *BHMT1*, *BHMT2* and *TCN2*, there was no evidence of a difference in the allelic and genotypic distribution between celiac patients and controls. The frequency of the *MTR* rs1805087 GG genotype in CD patients was lower than in controls (0.01 and 0.06, respectively), although statistical significance was not achieved. The difference between the combined rs1805087 GG + AG genotype frequencies in cases and controls also did not reach significance (*P* = 0.0842). The statistical power of presented study amounted to 50% for the *MTR* rs1805087 GG or AA genotype.Table 3Associations of homocysteine metabolism gene SNPs and risk of CD incidenceGeners no.GenotypeCD cases (frequency)Controls (frequency)Odds ratio (95% CI)*P*^a^Power (%)^b^Sample size for 80% power^b^*BHMT1*rs7356530AA49 (0.37)48 (0.30)Referent------AG64 (0.48)84 (0.52)0.7464 (0.446--1.248)0.264123674GG20 (0.15)28 (0.18)0.6997 (0.348--1.407)0.315418888AG + GG84 (0.63)112 (0.70)0.7347 (0.451--1.197)0.215324681MAF0.390.44--------*BHMT1*rs3733890GG73 (0.55)84 (0.53)Referent------AG50 (0.38)64 (0.40)0.8990 (0.553--1.460)0.666975330AA9 (0.07)12 (0.07)0.8630 (0.344--2.165)0.7533610164AG + AA59 (0.45)76 (0.47)0.8933 (0.562--1.419)0.632684531MAF0.260.28--------*BHMT2*rs526264TT49 (0.37)49 (0.31)Referent------AT62 (0.47)83 (0.52)0.7470 (0.446--1.250)0.266323676AA21 (0.16)28 (0.17)0.7500 (0.376--1.496)0.4137141329AT + AA83 (0.63)111 (0.69)0.7477 (0.459--1.218)0.242022758MAF0.390.43--------*BHMT2*rs625879GG50 (0.38)51 (0.32)Referent------GT62 (0.47)81 (0.51)0.7807 (0.468--1.302)0.342518939TT20 (0.15)28 (0.17)0.7286 (0.364--1.458)0.3703161109GT + TT82 (0.62)109 (0.68)0.7673 (0.473--1.245)0.283119900MAF0.390.43--------*CBS*844ins68WW^b^123 (0.92)140 (0.88)Referent------Wins11 (0.08)20 (0.12)0.6260 (0.288--1.359)0.232822731insins0 (0.00)0 (0.00)--------Wins + insins11 (0.08)20 (0.12)0.6260 (0.288--1.359)0.232822731MAF0.040.06--------*MTHFD1*rs2236225CC30 (0.23)50 (0.31)Referent------CT75 (0.56)79 (0.49)1.582 (0.911--2.748)0.102249278TT28 (0.21)31 (0.20)1.505 (0.760--2.980)0.239331489CT + TT103 (0.77)110 (0.69)1.561 (0.922--2.642)0.096338374MAF0.490.44--------*MTHFR*rs1801133CC53 (0.40)73 (0.46)Referent------CT70 (0.52)72 (0.45)1.339 (0.826--2.171)0.235724679TT11 (0.08)15 (0.09)1.010 (0.430--2.375)0.981751703634CT + TT81 (0.60)87 (0.54)1.282 (0.805--2.043)0.294718958MAF0.340.32--------*MTR*rs1805087AA87 (0.65)88 (0.55)Referent------AG45 (0.34)63 (0.39)0.7225 (0.445--1.172)0.187426598GG2 (0.01)9 (0.06)0.2248 (0.047--1.071)0.0603^c^50267AG + GG47 (0.35)72 (0.45)0.6603 (0.412--1.059)0.084241351MAF0.180.25--------*MTRR*rs1801394AA44 (0.33)47 (0.29)Referent------AG65 (0.49)83 (0.52)0.8365 (0.495--1.413)0.5041121799GG23 (0.17)30 (0.19)0.8189 (0.414--1.619)0.5653102526AG + GG88 (0.67)113 (0.71)0.8319 (0.506--1.367)0.4673111965MAF0.420.45--------*TCN2*rs1801198CC33 (0.25)50 (0.31)Referent------CG69 (0.52)80 (0.50)1.307 (0.758--2.254)0.335320805GG30 (0.23)30 (0.19)1.515 (0.775--2.962)0.223531483CG + GG99 (0.75)110 (0.69)1.364 (0.813--2.286)0.238622740MAF0.490.44--------^a^Chi-square analysis^b^Statistical power and sample size were calculated using the Power and Sample Size Calculation program v. 2.1.30 based on uncorrected chi-square test procedure (program parameters: α = 0.05, *n* = number of case patients)^c^Fisher exact test

The results of the exhaustive MDR analysis are summarised in Table [4](#Tab4){ref-type="table"}. No combination of possibly interactive polymorphisms reached statistical significance in predicting the incidence of CD.Table 4Results of gene--gene interactions analyzed by MDR methodGenes and rs numbersTesting balanced accuracy^a^Cross validation consistency^b^*P* value^c^*MTHFD1*\_rs22362250.44424/100.9980*MTR*\_rs1805087, *TCN2*\_rs18011980.51815/100.7260*MTHFD1*\_rs2236225, *TCN2*\_rs1801198, *BHMT2*\_rs6258790.48527/100.9480*MTHFR*\_rs1801133, *MTR*\_rs1805087, *MTRR*\_rs1801394, *BHMT2*\_rs5262640.50745/100.8130^a^Testing balanced accuracy of classification of cases and controls in the testing dataset calculated as (Sensitivity + Specificity)/2^b^Cross validation consistency is the number of times the model was selected as the best model after tenfold cross validation runs^c^Significance of accuracy, empirical *P* value based on 1,000 permutations

Discussion {#Sec7}
==========

The present investigation was undertaken to identify potential differences in the distribution of polymorphic variants of genes encoding key proteins of homocysteine metabolism between CD patients and the general population. Hyperhomocysteinemia, which is frequently due to deficiency of B vitamins and is usually, but inconsistently, rapidly corrected by a gluten-free diet in CD, might represent a link between undiagnosed CD and some of its complications \[[@CR2], [@CR7]\]. However, we observed no differences between CD patients and controls in the prevalence of the common c.677C\>T polymorphism of the *MTHFR* gene, the most important genetic determinant of blood homocysteine concentration in the general population \[[@CR9], [@CR11]\]. Our results regarding the distribution of the *MTHFR* c.677C\>T polymorphism confirm of the results of Dickey et al. \[[@CR27]\] and Hadithi et al. \[[@CR15]\], who also reported a lack of differences between CD patients and controls in the prevalence of the *MTHFR* c.677C\>T polymorphism. It is worth mentioning that there was also no difference in the distribution of the T-allele between CD women with at least two pregnancy losses within the first 3 months of pregnancy and CD women with at least one normal pregnancy and no history of spontaneous abortions \[[@CR23]\]. In contrast to the suggestions of Wilcox and Mattia (2006), it appears that there is no relevant role in the predisposition of CD patients to hyperhomocysteinemia and pregnancy complications due to a difference in the distribution of *MTHFR* c.677C\>T among celiac patients and the general population.

*MTR* rs1805087 polymorphism analysis showed a borderline difference between the polymorphism's distribution in celiac patients and controls. Although the results regarding the rs1805087 polymorphism's distribution require confirmation in larger studies, they also warrant some comments here. MTR is required by cells for the essential accumulation of folate \[[@CR28]\]. The role of the *MTR* rs1805087 GG genotype in homocysteine homeostasis and genomic methylation is debatable \[[@CR25]\]. Rs1805087 has been considerably investigated in humans with structural malformations \[[@CR29]--[@CR32]\]. In our group of celiac patients, the frequencies of the GG genotype and of the combined AG + GG genotype tended to be reduced in comparison to controls. The rs1805087 polymorphism, which is a polymorphic transition c.2756A\>G of the *MTR* gene leading to Asp919Gly substitution, has been shown to increase a woman's risk for giving birth to a child with isolated cleft lip with or without cleft palate in the Polish population \[[@CR25]\]. With this in mind, the results of the present study might indicate that Polish CD patients, who carry the G allele less frequently in comparison to the general population, may be less likely to have offspring with structural malformations than controls. There is only one source in the literature of the documented delivery of children with an orofacial cleft by celiac women with increased plasma homocysteine levels \[[@CR20]\]. There is a high prevalence of CD in family members of previously diagnosed celiac patients \[[@CR1]\]. However, despite a high incidence of both CD and craniofacial malformations in the general population, there are only two case reports, to the best our knowledge, of coexisting CD and an orofacial cleft (probably syndromic forms) \[[@CR33], [@CR34]\]. A literature search and our present observations do not support the hypothesis, recently popularized by Arakeri et al. \[[@CR22]\], of a link between parental CD and orofacial clefts of offspring.

We observed no differences in the distribution of polymorphic variants of *MTRR*, *MTHFD1*, *BHMT1*, *BHMT2*, and *TCN2* between celiac patients and controls. The MDR method has been successfully applied to detecting one-carbon metabolism's gene-to-gene interactions for various diseases \[[@CR26], [@CR35]\]. Previous biochemical and metabonomic studies have linked CD and alternations in methyl group metabolism \[[@CR14], [@CR24]\]. In contrast to these predictions, in our study the exhaustive MDR analysis revealed no statistically significant interactive effects of the polymorphic variants of the investigated genes on an individual's risk of being affected by CD.

To the best of the authors' knowledge, with the exception of studies devoted to the *MTHFR* 677C\>T polymorphism \[[@CR8], [@CR14], [@CR15], [@CR23], [@CR27]\], this is the first report on the frequency of genes encoding key proteins of homocysteine metabolism in celiac patients, and so we are unable to compare our results with data from other studies. Although the percentage of the *MTR* rs1805087 GG genotype is sixfold lower in celiac patients than in controls, the absolute number of only two homozygotes among CD patients precludes meaningful statistical comparisons between cases and controls with regard to other possible risk factors. The sample size was small and may strongly influence the presented results. It will be necessary to carry out related studies in larger sample sizes. Moreover, our results may underestimate the true difference in the distribution of the SNPs between celiac patients and controls, as we did not take into account the fact that potentially approx. 1% of our reference group may also have undiagnosed CD \[[@CR1], [@CR36]\]. It must be stressed that the selected polymorphisms represent only a fraction of the potential variation of the studied genes.

Restriction or exclusion of all animal foods may result in vitamin B~12~ deficiency, thereby affecting homocysteine homeostasis. The investigated ethnically homogenous population is mostly omnivorous. Recent studies of Y chromosome STR haplotype distribution showed homogeneity of paternal lineages in Poland and their distinctiveness from lineages from the neighboring countries \[[@CR37]\]. However, weaknesses of our study include the fact that we did not have data on food and supplements intake, as well as on plasma homocysteine and vitamin B levels.

In summary, the present findings revealed no differences in the distribution of polymorphic variants of genes encoding the main proteins involved in homocysteine/methyl group metabolism between Polish CD patients and controls. The only exception is *MTR* rs1805087, which tended to be less frequent in celiac patients in comparison to the general population. It may be hypothesized that a lower frequency of rs1805087 in celiac patients may modify their risk for having offspring with orofacial malformations. The pathophysiology of CD is not yet completely understood \[[@CR1]\]. Whether or not there is an increased risk for vitamin B-dependent malformations in offspring of untreated CD women, despite frequent vitamin B deficiencies, remains an unanswered question and requires further research.
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